Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition
Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition. The company was established in 2020 to accelerate clinical development of EoE therapies and build on the work initiated by Adare Pharmaceuticals, particularly APT-1011, which is currently in a Phase 3 clinical trial.